Jupiter to Earth: A Statin Helps People With Normal LDL-C and High hs-CRP, but What Does It Mean?
医学
内科学
瑞舒伐他汀
心脏病学
作者
Mehdi H. Shishehbor,Stanley L. Hazen
出处
期刊:Cleveland Clinic Journal of Medicine [Cleveland Clinic Journal of Medicine] 日期:2009-01-01卷期号:76 (1): 37-44被引量:15
标识
DOI:10.3949/ccjm.75a.08105
摘要
The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) (N Engl J Med 2008; 359:2195–2207) compared rosuvastatin (Crestor) 20 mg daily vs placebo in apparently healthy people who had levels of low-density lipoprotein cholesterol (LDL-C) lower than 130 mg/dL but elevated levels (≥ 2 mg/L) of high-sensitivity C-reactive protein (hs-CRP). Rosuvastatin treatment lowered LDL-C levels by 50% and hs-CRP levels by 37%, accompanied by a 44% relative risk reduction in the composite end point of unstable angina, revascularization, and confirmed death from cardiovascular causes. In absolute terms, 95 people had to be treated over 2 years to prevent one event. There was, however, a higher incidence of diabetes in the rosuvastatin group.